The recent surge in funding into specialized pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling casino "High Stakeholder Pharma." While the potential for game-changing treatments and impressive returns is clear, the connected risks are also notabl